CHMP to review Tysabri as PML cases hit 23
This article was originally published in Scrip
The CHMP is to review the "benefits and risks" of Elan/Biogen Idec's Tysabri (natalizumab) for the treatment of multiple sclerosis, based on an increasing rate of progressive multifocal leucoencephalopathy (PML). The CHMP reported that 23 cases of PML occurred worldwide since launch, higher than the 13 previously disclosed. Biogen Idec shares dropped by 7% on Nasdaq on October 23rd on the news, whereas Elan shares fell by around 17.5% on the NYSE.
You may also be interested in...
ChemoCentryx has successfully completed its initial public offering on Nasdaq, raising $45 million to help support its multiple R&D programmes. It sold 4.5 million shares at $10, a somewhat less ambitious debut than it had originally planned in January when it wanted to sell four million shares at $14-$16. The reduced offer is a sign of the challenging nature of the IPO market, but ChemoCentryx's assessment of its own worth was at least closer to the market’s assessment that Cempra which got its IPO away on 6 February at valuation that was less than two-thirds of that implied by its initial prospectus (scripintelligence.com, 7 February 2012).
Ampio Pharmaceuticals, a development-stage company, initially raised $15 million which was boosted to $16.9 million by the exercise of overallotments by brokers. The shares were offered at $3.25, an 8.5% discount to the closing price of $3.66 on 12 July. The market pushed them down slightly further to 3.21 on 13 July.
Verastem, a cancer stem cells startup, has moved quickly to build its pipeline just five months after an initial public offering. Management at the Cambridge, Massachusetts firm believes that recent moves have accelerated Verastem's clinical development plans by a year.